Sponsor Check › Person
Related person on Form D filings · address states/countries as listed: CA, TX, Ireland (as filed: L2), MA, PA · listed Jul 16, 2009 → Jul 12, 2024
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:56 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:56 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:56 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
4 of 38 offerings report sales commissions totalling $8,132,738; 0 report finder's fees; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Nov 1, 2024 D File 021-528494 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jul 12, 2024 D File 021-518549 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 9, 2024 D File 021-504871 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 22, 2023 D File 021-500662 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 21, 2023 D File 021-487531 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 20, 2023 D File 021-476362 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 2, 2022 D File 021-466472 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 21, 2022 D/A File 021-448741 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 24, 2021 D File 021-414543 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 22, 2021 D/A File 021-371827 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 14, 2021 D File 021-399537 | $2,435,860 (est.) | $0 | $0 | BA Securities LLC BrokerCheck CRD 153489 ↗ Far Hills Group, LLC BrokerCheck CRD 32243 ↗ |
| EDGAR ↗ | Jun 18, 2020 D File 021-369265 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 24, 2020 D/A File 021-278526 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 24, 2020 D File 021-365710 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 26, 2020 D/A File 021-314554 | $0 (est.) | $0 (est.) | $0 (est.) An affiliate of the general partner (or its designee) will receive an annual fee for management services equal to a percentage of each investor's subscription to the Issuer, as specified in the Issuer's partnership agreement. | Far Hills Group LLC BrokerCheck CRD 32243 ↗ BA Securities, LLC BrokerCheck CRD 153489 ↗ |
| EDGAR ↗ | Jan 28, 2020 D/A File 021-347004 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 1, 2019 D/A File 021-327684 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 16, 2017 D File 021-288881 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 2, 2017 D/A File 021-236281 | $0 | $0 | $0 (est.) An affiliate of the general partner (or its designee) will receive an annual fee for management services equal to a percentage of each investor's subscription to the Issuer, as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Feb 16, 2017 D/A File 021-246410 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 11, 2016 D/A File 021-146407 | $3,138,096 (est.) | $0 (est.) | $0 (est.) Issuer's investment manager and its principals receive a management fee based on the value of the issuer's assets and/or a performance allocation based on the issuer's profits, calculated per the offering documents; includes proceeds from a master fund. | Far Hills Group LLC BrokerCheck CRD 32243 ↗ Direct Access Partners, LLC BrokerCheck CRD 120950 ↗ |
| EDGAR ↗ | Oct 11, 2016 D/A File 021-146405 | $1,771,282 (est.) | $0 (est.) | $0 (est.) Issuer's managing member and its principals receive a management fee based on the value of the issuer's assets and/or a performance allocation based on the issuer's profits, calculated per the offering documents; includes proceeds from a feeder fund. | Far Hills Group LLC BrokerCheck CRD 32243 ↗ |
| EDGAR ↗ | Dec 30, 2015 D File 021-254171 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 21, 2015 D File 021-240360 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 1, 2015 D File 021-239002 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 3, 2014 D File 021-225788 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 29, 2013 D/A File 021-150376 | $0 | $0 | $0 (est.) An affiliate of the general partner (or its designee) will receive an annual fee for management services equal to a percentage of each investor's subscription to the Issuer, as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Dec 28, 2012 D File 021-189143 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 28, 2012 D File 021-189144 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 12, 2012 D File 021-188236 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 2, 2012 D File 021-186414 | $787,500 (est.) | $0 | $0 | Ferghana Securities, Inc. BrokerCheck CRD 43430 ↗ |
| EDGAR ↗ | Jan 30, 2012 D File 021-172591 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 23, 2011 D File 021-164825 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 9, 2011 D File 021-164097 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 26, 2011 D/A File 021-152195 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 9, 2010 D/A File 021-144981 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 20, 2009 D/A File 021-88136 | $0 | $0 | $0 Funds to be used for working capital. | None listed on this filing |
| EDGAR ↗ | Jul 16, 2009 D File 021-132857 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Axonis Therapeutics, Inc. | Director | Nov 1, 2024 | D | $115,000,000 similar: $2,000,000–$19,999,994 | $46,000,000 | 19 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | venBio Global Strategic Fund V, L.P. group: Venbio | Executive Officer | Jul 12, 2024 | D | Indefinite similar: $155,000–$5,250,000 | $504,700,000 | 162 similar: 4–27 | $62,500 similar: $1,000–$100,000 |
| EDGAR ↗ | Attralus, Inc. | Director | Feb 9, 2024 | D | $55,999,931 similar: $2,000,000–$19,999,994 | $55,999,931 | 12 similar: 2–16 | $24,405 similar: $10,000–$50,000 |
| EDGAR ↗ | INSAMO INC. | Director | Dec 22, 2023 | D | $2,300,000 similar: $2,000,000–$19,999,994 | $2,300,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NFlection Therapeutics, Inc. | Director | Jul 21, 2023 | D | $4,000,000 similar: $2,000,000–$19,999,994 | $4,000,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | INSAMO INC. | Director | Mar 20, 2023 | D | $10,000,000 similar: $2,000,000–$19,999,994 | $9,524,998 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | FOG PHARMACEUTICALS, INC. | Director | Dec 2, 2022 | D | $177,999,922 similar: $1,694,259–$16,000,000 | $177,999,922 | 24 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | NFlection Therapeutics, Inc. | Director | Jun 21, 2022 | D/A | $30,000,000 similar: $2,000,000–$19,999,994 | $20,000,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NFlection Therapeutics, Inc. | Director | Jun 10, 2022 | D | $20,000,000 similar: $2,000,000–$19,999,994 | $10,000,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Attralus, Inc. | Director | Sep 24, 2021 | D | $116,599,889 similar: $2,000,000–$19,999,994 | $116,599,889 | 22 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Tallac Therapeutics, Inc. | Director | Jul 22, 2021 | D/A | $61,616,192 similar: $829,831–$9,999,998 | $61,616,192 | 12 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | venBio Global Strategic Fund IV, L.P. group: Venbio | Executive Officer | May 14, 2021 | D | $550,000,000 similar: $155,000–$5,250,000 | $549,936,000 | 147 similar: 4–27 | $125,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Tallac Therapeutics, Inc. | Director | Jul 27, 2020 | D | $40,350,000 similar: $829,831–$9,999,998 | $21,175,000 | 10 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Jun 18, 2020 | D | $100,083,274 similar: $2,000,000–$19,999,994 | $85,083,280 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NFlection Therapeutics, Inc. | Director | Apr 24, 2020 | D/A | $24,000,000 similar: $2,000,000–$19,999,994 | $20,000,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Apr 24, 2020 | D | $10,000,000 similar: $2,000,000–$19,999,994 | $10,000,000 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | venBio Global Strategic Fund III, L.P. group: Venbio | Director Director of the General Partner of the Issuer's General Partner | Mar 26, 2020 | D/A | $386,055,000 similar: $155,000–$5,250,000 | $386,055,000 | 100 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Jan 28, 2020 | D/A | $15,999,999 similar: $2,000,000–$19,999,994 | $15,999,999 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Aug 20, 2019 | D | $15,999,999 similar: $2,000,000–$19,999,994 | $7,999,996 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Apr 1, 2019 | D/A | $21,999,995 similar: $2,000,000–$19,999,994 | $21,999,995 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | venBio Global Strategic Fund III, L.P. group: Venbio | Director Director of the General Partner of the Issuer's General Partner | Mar 26, 2019 | D/A | $350,000,000 similar: $155,000–$5,250,000 | $118,000,000 | 8 similar: 4–27 | $5,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Dec 12, 2018 | D | $21,999,995 similar: $2,000,000–$19,999,994 | $10,999,998 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | venBio Global Strategic Fund III, L.P. group: Venbio | Director Director of the General Partner of the Issuer's General Partner | Jun 13, 2018 | D | $350,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Jun 16, 2017 | D | $27,000,000 similar: $2,000,000–$19,999,994 | $27,000,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | venBio Global Strategic Fund II L.P. group: Venbio | Director Director of the General Partner of the Issuer's General Partner | Mar 2, 2017 | D/A | $337,000,000 similar: $155,000–$5,250,000 | $337,000,000 | 31 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Feb 16, 2017 | D/A | $25,000,000 similar: $2,000,000–$19,999,994 | $25,000,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NFlection Therapeutics, Inc. | Director | Jan 17, 2017 | D | $14,000,000 similar: $2,000,000–$19,999,994 | $1,400,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Avoro Life Sciences Offshore Fund Ltd. group: Avoro | Executive Officer Managing member of venBio Select Advisor LLC. | Oct 11, 2016 | D/A | Indefinite similar: $155,000–$5,250,000 | $249,289,000 | 96 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Avoro Life Sciences Fund LLC group: Avoro | Executive Officer Managing member of venBio Select Advisor LLC. | Oct 11, 2016 | D/A | Indefinite similar: $155,000–$5,250,000 | $412,916,742 | 108 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Jun 30, 2016 | D/A | $20,000,000 similar: $2,000,000–$19,999,994 | $20,000,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | venBio Global Strategic Fund II L.P. group: Venbio | Director Director of the General Partner of the Issuer's General Partner | Mar 18, 2016 | D/A | $303,000,000 similar: $155,000–$5,250,000 | $288,000,000 | 22 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Solstice Biologics LLC group: Venbio | Executive Officer, Director, Promoter Mr. Goodman is the President, Chief Executive Officer and a member of the Board of Managers of the Issuer. | Dec 30, 2015 | D | $4,000,000 similar: $1,694,259–$16,000,000 | $4,000,000 | 2 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Avoro Life Sciences Offshore Fund Ltd. group: Avoro | Executive Officer Managing member of venBio Select Advisor LLC. | Oct 9, 2015 | D/A | Indefinite similar: $155,000–$5,250,000 | $178,486,500 | 82 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Avoro Life Sciences Fund LLC group: Avoro | Executive Officer Managing member of venBio Select Advisor LLC. | Oct 9, 2015 | D/A | Indefinite similar: $155,000–$5,250,000 | $292,582,529 | 96 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Checkmate Pharmaceuticals, Inc. | Director | Aug 25, 2015 | D | $20,030,000 similar: $1,694,259–$16,000,000 | $10,030,000 | 2 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Alexo Therapeutics Ltd | Director | May 21, 2015 | D | $36,005,425 similar: $2,000,000–$19,999,994 | $18,022,500 | 14 similar: 2–16 | $37,500 similar: $10,000–$50,000 |
| EDGAR ↗ | SYNLOGIC, INC. group: Synlogic | Director | May 1, 2015 | D | $45,000,000 similar: $1,694,259–$16,000,000 | $41,789,527 | 24 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | venBio Global Strategic Fund II L.P. group: Venbio | Director Director of the General Partner of the Issuer's General Partner | Mar 19, 2015 | D | $250,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Avoro Life Sciences Offshore Fund Ltd. group: Avoro | Executive Officer Managing member of venBio Select Advisor LLC. | Oct 17, 2014 | D/A | Indefinite similar: $155,000–$5,250,000 | $65,840,000 | 51 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Avoro Life Sciences Fund LLC group: Avoro | Executive Officer Managing member of venBio Select Advisor LLC. | Oct 17, 2014 | D/A | Indefinite similar: $155,000–$5,250,000 | $123,974,500 | 42 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Solstice Biologics LLC group: Venbio | Executive Officer, Director Mr. Goodman is President/CEO and Manager of the Issuer. | Oct 3, 2014 | D | $7,500,000 similar: $1,694,259–$16,000,000 | $7,500,000 | 2 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | venBio Global Strategic Fund, L.P. group: Venbio | Director Director of the General Partner of the Issuer's General Partner | Oct 29, 2013 | D/A | $237,000,000 similar: $155,000–$5,250,000 | $177,000,000 | 4 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Solstice Biologics LLC group: Venbio | Executive Officer, Director Mr. Goodman is President/CEO and Manager of the Issuer. | Dec 28, 2012 | D | $7,500,000 | $7,500,000 | 2 | No minimum reported |
| EDGAR ↗ | Labrys Biologics, Inc. group: Venbio | Executive Officer, Director | Dec 28, 2012 | D | $30,999,997 | $14,588,234 | 5 | No minimum reported |
| EDGAR ↗ | Solstice Biologics LLC group: Venbio | Executive Officer, Director Mr. Goodman is President/CEO and Manager of the Issuer. | Dec 12, 2012 | D | $3,000,000 | $3,000,000 | 1 | No minimum reported |
| EDGAR ↗ | SYNLOGIC, INC. group: Synlogic | Director | Nov 2, 2012 | D | $34,499,990 | $17,249,995 | 17 | No minimum reported |
| EDGAR ↗ | venBio Global Strategic Fund, L.P. group: Venbio | Director Director of the General Partner of the Issuer's General Partner | Oct 31, 2012 | D/A | $177,500,000 | $177,000,000 | 4 | No minimum reported |
| EDGAR ↗ | LIMERICK BIOPHARMA INC | Director | Jan 30, 2012 | D | $480,000 | $480,000 | 5 | No minimum reported |
| EDGAR ↗ | venBio Global Strategic Fund, L.P. group: Venbio | Director Director of the General Partner of the Issuer's General Partner | Nov 3, 2011 | D/A | $177,500,000 | $175,000,000 | 3 | No minimum reported |
| EDGAR ↗ | SYNLOGIC, INC. group: Synlogic | Director | Aug 23, 2011 | D | $1,500,000 | $1,500,000 | 9 | No minimum reported |
| EDGAR ↗ | Second Genome, Inc. | Director | Aug 9, 2011 | D | $4,999,999 | $4,999,999 | 12 | No minimum reported |
| EDGAR ↗ | LIMERICK BIOPHARMA INC | Director | Jul 26, 2011 | D/A | $13,228,591 | $9,939,415 | 13 | No minimum reported |
| EDGAR ↗ | LIMERICK BIOPHARMA INC | Director | Mar 10, 2011 | D/A | $6,935,000 | $6,889,415 | 13 | No minimum reported |
| EDGAR ↗ | LIMERICK BIOPHARMA INC | Director | Dec 20, 2010 | D | $3,585,000 | $3,585,000 | 13 | No minimum reported |
| EDGAR ↗ | venBio Global Strategic Fund, L.P. group: Venbio | Director Director of the General Partner of the Issuer's General Partner | Nov 12, 2010 | D | $175,000,000 | $75,000,000 | 1 | No minimum reported |
| EDGAR ↗ | iPierian, Inc. | Director | Nov 9, 2010 | D/A | $28,970,000 | $28,970,000 | 20 | No minimum reported |
| EDGAR ↗ | iPierian, Inc. | Director | Sep 9, 2010 | D/A | $28,470,000 | $28,470,000 | 19 | No minimum reported |
| EDGAR ↗ | iPierian, Inc. | Director | Jul 15, 2010 | D | $25,000,000 | $22,390,001 | 13 | No minimum reported |
| EDGAR ↗ | LIMERICK BIOPHARMA INC | Director | Aug 20, 2009 | D/A | $15,380,000 | $15,380,000 | 17 | No minimum reported |
| EDGAR ↗ | iPierian, Inc. | Director | Jul 16, 2009 | D | $938,590 | $938,590 | 4 | No minimum reported |
| EDGAR ↗ | iPierian, Inc. | Director | Jul 16, 2009 | D | $11,499,998 | $6,499,999 | 4 | No minimum reported |
| EDGAR ↗ | LIMERICK BIOPHARMA INC | Director | Jul 16, 2009 | D | $15,150,000 | $15,000,000 | 7 | No minimum reported |
| EDGAR ↗ | LIMERICK BIOPHARMA INC | Director | Jun 5, 2009 | D | $1,500,000 | $1,500,000 | 5 | No minimum reported |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); Pooled Investment Fund / 506(b) (83,801 filings); Pharmaceuticals / 506(b) (800 filings); Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
People and management entities the issuers listed as related persons on the same Form D filings as Corey Goodman. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Corey Goodman appears on a new Form D, or when a court case or SEC action is matched to them. See plans →